secwatch.observer — SEC 8-K summary
======================================

Issuer:     UroGen Pharma Ltd. (URGN)
CIK:        0001668243
Form:       8-K
Filed at:   2024-01-02T23:59:59+00:00
Accession:  0001193125-24-000244
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

UroGen amends manufacturing pact for UGN-102; extends term to 2027, commits €4.4M for equipment
--------------------------------------------------------------------------------

- Amendment to manufacturing agreement with Cenexi extends initial term to April 1, 2027.
- UroGen revised minimum annual quantity forecasts for bulk mitomycin purchases.
- Company agreed to reimburse up to €4.4 million for dedicated capital equipment for UGN-102 production.
- Amendment is in anticipation of potential approval and launch of UGN-102, a mitomycin product for low-grade upper tract urothelial cancer.
- Parties will negotiate final terms on equipment purchase, installation, and validation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1668243/000119312524000244/0001193125-24-000244-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1668243/000119312524000244/d231255d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-000244

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer